Pediatric Allergy/Immunology & Rheumatology Research
Hypereosinophilic Syndrome (HES) Study for Adults
Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)
AGE: 12+ years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Study
HEALTHY PARTICIPANTS: No
HEALTHY PARTICIPANTS: No
CONDITION: Hypereosinophilic Syndrome (HES)
LOCATION: University Hospitals Rainbow Babies & Children’s
LOCATION: University Hospitals Rainbow Babies & Children’s
Learn More About This Research Study
For more information, please contact study coordinator, Erica Denallo at 440-879-4136 and leave a message or click the link to the study survey below.
Study Purpose
The purpose of this study is to see if benralizumab, given as injections under the skin, can help control HES better if it is added to available standard of care HES medications.
Who Can Participate
Participants 12 years of age or older diagnosed with Hypereosinophilic Syndrome may be eligible for this study.